Perspective Therapeutics' VMT-α-NET Protocols Presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium

Perspective Therapeutics, a leading medical technology and radiopharmaceutical company, recently presented two investigator-initiated trials at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium in Montreal, Canada. These trials aim to explore the potential of Perspective’s innovative treatment, Pb-212-VMT-alpha-NET, in managing neuroendocrine tumors (NETs) that have been challenging to treat.

The first presentation focused on a Phase 1 trial of Pb-212-VMT-alpha-NET in patients with metastatic or inoperable somatostatin receptor positive (SSTR+) tumors. The trial aims to investigate whether this new treatment can improve the management of patients who have not received prior radioligand therapy. The study will evaluate the safety, tolerability, and pharmacokinetic properties of Pb-212-VMT-alpha-NET in five different SSTR+ tumors, including gastrointestinal neuroendocrine tumors (GI-NET), pheochromocytoma and paraganglioma (PPGL), small cell lung cancer (SCLC), renal cell carcinoma (RCC), and head and neck (H&N). Enrollment for this study is expected to begin in the first quarter of 2024.

The second presentation outlined a Phase 1/2 trial of Pb-212-VMT-alpha-NET in GI neuroendocrine tumors and pheochromocytoma/paraganglioma previously treated with radioligand therapy. This trial aims to determine whether Pb-212-VMT-alpha-NET can improve the management of patients who have progressed on beta-emitting radioligand therapy. The study will evaluate the safety, tolerability, and pharmacokinetic properties of Pb-212-VMT-alpha-NET in SSTR+ metastatic GI neuroendocrine tumors (GI-NETs) and pheochromocytoma/paraganglioma (PPGL) tumors. Enrollment for this study is also expected to commence in the first quarter of 2024.

Perspective Therapeutics’ Chief Executive Officer, Thijs Spoor, expressed excitement about expanding clinical studies to a wider range of cancer types, potentially offering new therapeutic options for patients with difficult-to-treat tumors. The Chief Medical Officer, Markus Puhlmann, highlighted the importance of investigating the safety and efficacy of Pb-212-VMT-alpha-NET in these expanded patient populations, where the unmet need is greatest.

Neuroendocrine tumors are a rare and challenging type of cancer that can originate in various parts of the body, such as the gut or lungs. Currently, there are no approved targeted radiopharmaceuticals for NETs patients outside of the gastroenteropancreatic indication. According to cancer.net, approximately 12,000 people in the United States are diagnosed with NETs each year, and there are approximately 175,000 people living with this diagnosis.

Perspective Therapeutics is at the forefront of developing advanced treatment applications for cancers throughout the body. Their proprietary technology utilizes the alpha-emitting isotope Lead-212 to deliver powerful radiation specifically to cancer cells using specialized targeting peptides. This “theranostic” approach combines personalized imaging diagnostics with targeted therapy, potentially improving efficacy and minimizing toxicity associated with other cancer treatments.

In addition to their neuroendocrine tumor program, Perspective Therapeutics is also developing treatments for metastatic melanoma. Their melanoma program, VMT01, has entered Phase 1/2a imaging and therapy trials at several leading academic institutions in the United States.

With their commitment to innovation and addressing unmet medical needs, Perspective Therapeutics is poised to make a significant impact in the field of cancer treatment. Their clinical trials and advancements in targeted alpha particle therapy offer hope to patients with challenging-to-treat tumors, providing potential new options for improved outcomes and quality of life. To learn more about Perspective Therapeutics and their groundbreaking research, visit their website at www.perspectivetherapeutics.com.